Ann Brunson

Ann Brunson

Auto-generated profile, based on publicly available information

Ann Brunson

Center for Oncology Hematology Outcomes Research and Training, Division of Hematology and Oncology University of California Davis Comprehensive Cancer Center Sacramento California USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
AMAnjlee Mahajan
Anjlee Mahajan
ABAnn Brunson
Ann Brunson
OAOyebimpe Adesina
Oyebimpe Adesina
TKTheresa H.M. Keegan
Theresa H.M. Keegan
TWTed Wun
Ted Wun
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality for patients with malignancy and varies by primary cancer type, stage, and therapy. We aimed to characterize the incidence, risk factors, temporal trends, and the effect on mortality of CAT. The California Cancer Registry was linked to the statewide hospitalization database to identify individuals with the 13 most common malignancies diagnosed between 2005 and 2017 and determine the 6- and 12-month cumulative incidence of CAT by venous thromboembolism (VTE) location, tumor type, and stage after adjusting for competing risk of death. Cox proportional hazard regression models were used to determine risk factors associated with CAT and the effect of CAT on all-cause mortality. 942 019 patients with cancer were identified; 62 003 (6.6%) had an incident diagnosis of CAT. Patients with pancreatic, brain, ovarian, and lung cancer had the highest, and patients with breast and prostate cancer had the lowest 12-month cumulative incidence of CAT. For most malignancies, men, those with metastatic disease and more comorbidities, and African Americans (vs non-Hispanic Whites) were at highest risk for CAT. Patients diagnosed with cancer between 2014 and 2017 had a higher risk of CAT compared with those diagnosed between 2005 and 2007. CAT was associated with increased overall mortality for all malignancies (HR ranges 1.89 to 4.79). The incidence of CAT increased over time and was driven by an increase in pulmonary embolism±deep vein thrombosis (PE±DVT). CAT incidence varies based on tumor type and stage and on individual risk factors including gender, race/ethnicity, and comorbidities. For all tumor types, CAT is associated with an increased mortality.

3 April 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ABAnn Brunson
Ann Brunson
ALAmy Lei
Amy Lei
ARAaron S. Rosenberg
Aaron S. Rosenberg
RWRichard H. White
Richard H. White
TKTheresa Keegan
Theresa Keegan
TWTed Wun
Ted Wun

24 May 2016 in Circulation
Verified
Journal Article
Closed access
PDF file
RWRichard H. White
Richard H. White
ABAnn Brunson
Ann Brunson
PRPatrick S. Romano
Patrick S. Romano
ZLZhongmin Li
Zhongmin Li
TWTed Wun
Ted Wun
Background—Evidence that vena-cava filters (VCFs) are beneficial is limited.

1 December 2016 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MHMisty Humphries
Misty Humphries
ABAnn Brunson
Ann Brunson
CLChin-Shang Li
Chin-Shang Li
JMJoy Melnikow
Joy Melnikow
PRPatrick S. Romano
Patrick S. Romano

1 January 2016 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
MHMisty Humphries
Misty Humphries
ABAnn Brunson
Ann Brunson
NHNasim Hedayati
Nasim Hedayati
PRPatrick Romano
Patrick Romano
JMJoy Melnkow
Joy Melnkow

17 April 2017 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
GHGwendolyn Ho
Gwendolyn Ho
BJBrian A Jonas
Brian A Jonas
QLQian Li
Qian Li
ABAnn Brunson
Ann Brunson
TWTed Wun
Ted Wun
TKTheresa H. M. Keegan
Theresa H. M. Keegan
Summary: Few studies have evaluated the impact of complications, sociodemographic and clinical factors on early mortality (death ≤60 days from diagnosis) in acute myeloid leukaemia (AML) patients. Using data from the California Cancer Registry linked to hospital discharge records from 1999 to 2012, we identified patients aged ≥15 years with AML who received inpatient treatment (N = 6359). Multivariate logistic regression analyses were used to assess the association of complications with early mortality, adjusting for sociodemographic factors, comorbidities and hospital type. Early mortality decreased over time (25·3%, 1999–2000; 16·8%, 2011–2012) across all age groups, but was higher in older patients (6·9%, 15–39, 11·4%, 40–54, 18·6% 55–65, and 35·8%, >65 years). Major bleeding [Odds ratio (OR) 1·5, 95% confidence interval (CI) 1·3–1·9], liver failure (OR 1·9, 95% CI 1·1–3·1), renal failure (OR 2·4, 95% CI 2·0–2·9), respiratory failure (OR 7·6, 95% CI 6·2–9·3) and cardiac arrest (OR 15·8, 95% CI 8·7–28·6) were associated with early mortality. Higher early mortality was also associated with single marital status, low neighbourhood socioeconomic status, lack of health insurance and comorbidities. Treatment at National Cancer Institute‐designated cancer centres was associated with lower early mortality (OR 0·5, 95% CI 0·4–0·6). In conclusion, organ dysfunction, hospital type and sociodemographic factors impact early mortality. Further studies should investigate how differences in healthcare delivery affect early mortality.